Clinical Trial Update: Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for cediranib maleate with or without lenalidomide in thyroid cancer completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Follicular Thyroid Carcinoma
• Hurthle Cell Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Unresectable Thyroid Carcinoma

Drugs mentioned

• Cediranib Maleate (cediranib)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-15